Rebecca M. Platoff

Rebecca M. Platoff

Auto-generated profile, based on publicly available information

Rebecca M. Platoff

Cooper University Hospital, Department of Surgery, Camden, NJ, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2022 in The Lancet Global Health
Verified
Journal Article
Open access
CSCatherine A Shaw
Catherine A Shaw
RPRiinu Pius
Riinu Pius
TDThomas M Drake
Thomas M Drake
LNLisa Norman
Lisa Norman
AAAdesoji O Ademuyiwa
Adesoji O Ademuyiwa
JLJean Wilguens Lartigue
Jean Wilguens Lartigue
Early death after cancer surgery is higher in low-income and middle-income countries (LMICs) compared with in high-income countries, yet the impact of facility characteristics on early postoperative outcomes is unknown. The aim of this study was to examine the association between hospital infrastructure, resource availability, and processes on early outcomes after cancer surgery worldwide. A multimethods analysis was performed as part of the GlobalSurg 3 study—a multicentre, international, prospective cohort study of patients who had surgery for breast, colorectal, or gastric cancer. The primary outcomes were 30-day mortality and 30-day major complication rates. Potentially beneficial hospital facilities were identified by variable selection to select those associated with 30-day mortality. Adjusted outcomes were determined using generalised estimating equations to account for patient characteristics and country-income group, with population stratification by hospital. Between April 1, 2018, and April 23, 2019, facility-level data were collected for 9685 patients across 238 hospitals in 66 countries (91 hospitals in 20 high-income countries; 57 hospitals in 19 upper-middle-income countries; and 90 hospitals in 27 low-income to lower-middle-income countries). The availability of five hospital facilities was inversely associated with mortality: ultrasound, CT scanner, critical care unit, opioid analgesia, and oncologist. After adjustment for case-mix and country income group, hospitals with three or fewer of these facilities (62 hospitals, 1294 patients) had higher mortality compared with those with four or five (adjusted odds ratio [OR] 3·85 [95% CI 2·58–5·75]; p<0·0001), with excess mortality predominantly explained by a limited capacity to rescue following the development of major complications (63·0% vs 82·7%; OR 0·35 [0·23–0·53]; p<0·0001). Across LMICs, improvements in hospital facilities would prevent one to three deaths for every 100 patients undergoing surgery for cancer. Hospitals with higher levels of infrastructure and resources have better outcomes after cancer surgery, independent of country income. Without urgent strengthening of hospital infrastructure and resources, the reductions in cancer-associated mortality associated with improved access will not be realised. National Institute for Health and Care Research.

1 October 2020 in Clinical Breast Cancer
Verified
Journal Article
Closed access
NPNikolay Popnikolov
Nikolay Popnikolov
KBKatarzyna Brzezinska
Katarzyna Brzezinska
RPRebecca M. Platoff
Rebecca M. Platoff
RBRhonda Binnebose
Rhonda Binnebose
RRRene Rothstein-Rubin
Rene Rothstein-Rubin
AWAmanda Woodworth
Amanda Woodworth

19 May 2023 in The American Surgeon™
Verified
Journal Article
Closed access
TETaylor M. Evangelisti
Taylor M. Evangelisti
RPRebecca M. Platoff
Rebecca M. Platoff
PKPolina Khrizman
Polina Khrizman
JMJamin C. Morrison
Jamin C. Morrison
UJUpasana Joneja
Upasana Joneja
SMSteven J. McClane
Steven J. McClane
Rectal small cell carcinoma is a rare and aggressive cancer subtype for which a consensus of optimal treatment has not yet been reached. This cancer presents a difficult surgical problem, and thus, the mainstay of treatment tends to mirror that of small cell carcinoma of the lung (chemotherapy, radiation therapy, and immune modulators). This brief report highlights current treatment options available for this rare and difficult entity. There is a significant need for large-center clinical trials and prospective studies to help determine the best treatment regimen to effectively care for patients with small cell carcinoma of the rectum.